| Literature DB >> 34215854 |
Marc Ansari1,2, Kateryna Petrykey3,4, Mohamed Aziz Rezgui3, Veronica Del Vecchio3,4, Jacques Cortyl3, Milad Ameur3,4, Tiago Nava1,2, Patrick Beaulieu3, Pascal St-Onge3, Simona Jurkovic Mlakar1,2, Chakradhara Rao S Uppugunduri1,2, Yves Théoret3,4,5, Imke H Bartelink6,7, Jaap-Jan Boelens6,8, Robbert G M Bredius9, Jean-Hugues Dalle10, Victor Lewis11, Bill S Kangarloo11, Selim Corbacioglu12, Daniel Sinnett3,13, Henrique Bittencourt3,13, Maja Krajinovic14,15,16,17.
Abstract
The most frequent complication of allogeneic hematopoietic stem cell transplantation is acute Graft versus Host Disease (aGVHD). Proliferation and differentiation of donor T cells initiate inflammatory response affecting the skin, liver, and gastrointestinal tract. Besides recipient-donor HLA disparities, disease type, and the conditioning regimen, variability in the non-HLA genotype have an impact on aGVHD onset, and genetic variability of key cytokines and chemokines was associated with increased risk of aGVHD. To get further insight into the recipient genetic component of aGVHD grades 2-4 in pediatric patients, we performed an exome-wide association study in a discovery cohort (n = 87). Nine loci sustained correction for multiple testing and were analyzed in a validation group (n = 168). Significant associations were replicated for ERC1 rs1046473, PLEK rs3816281, NOP9 rs2332320 and SPRED1 rs11634702 variants through the interaction with non-genetic factors. The ERC1 variant was significant among patients that received the transplant from HLA-matched related individuals (p = 0.03), bone marrow stem cells recipients (p = 0.007), and serotherapy-negative patients (p = 0.004). NOP9, PLEK, and SPRED1 effects were modulated by stem cell source, and serotherapy (p < 0.05). Furthermore, ERC1 and PLEK SNPs correlated with aGVHD 3-4 independently of non-genetic covariates (p = 0.02 and p = 0.003). This study provides additional insight into the genetic component of moderate to severe aGVHD.Entities:
Mesh:
Year: 2021 PMID: 34215854 DOI: 10.1038/s41409-021-01386-8
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.174